| |
 |
Therapeutic Expertise |
|
|
 |
 |
Medical Directors |
|
|
 |
|
|
SYNARC is the world leader in imaging core lab services for oncology studies.
SYNARC is the world's largest imaging core lab dedicated to clinical trials. At our centers in the United States, Europe, and Asia, we are currently at work on clinical trials in a broad range of oncology-related indications. Through our experienced project managers, scientific staff, and in-house and external radiologists, we provide our clients with the industry's highest quality of service involving CT, DCE-MRI, MRI, PET, SPECT, NM, DXA, MRS, ECHO, and other imaging modalities central to the success of oncology clinical trials. Our experts are top-rated scientists and clinicians at the forefront of oncology research.
StudyDirect
StudyDirect is our 21 CRF Part 11 clinical imaging management system which provides state-of-the-art image analysis tools for our in-house and external radiologists. With more than four million images uploaded through our Web portal, SynarcConnect, we work with sites throughout the world to effectively capture high-quality images and data to efficiently meet your timelines. Our industry-leading, Web-based reporting provides you with the immediate insight into key metrics relating to your study to ensure timelines are met.
Regulatory compliance
SYNARC’s systems and processes have been audited hundreds of times by the world’s leading pharmaceutical and medical device companies, as well as the FDA and EMA. An imaging provider’s quality management system is a key requirement for successful regulatory submissions. Our expertise in dealing with global agencies’ procedures will help your organization navigate the regulatory approval process more effectively and cost efficiently. |
|
 |
Synarc's Oncology Expertise |
Cancer Indications
- Antiangiogenesis
- Breast cancer
- Gastrointestinal malignancies
- Glioma and Glioblastoma
- Gynecological malignancies
- Hepatocellular carcinoma
- Lung cancer
- Lymphoma
- Melanoma
- Mesothelioma
- Pancriaticobiliary malignancies
- Prostate cancer
- Renal cell carcinoma
Safety and Efficacy Endpoints
- RECIST 1.0
- RECIST 1.1
- IHP/Cheson
- Choi
- Tumor volume
- Pharmacokinetics
- Left Ventricular Ejection Fraction (LVEF)
- Bone Mineral Density (BMD)
Imaging Modalities
- CT
- MRI, DCE-MRI
- PET
- NM
- SPECT
- DXA
- MRS
- ECHO
|
|
 |
|
|